Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06006143 · ClinicalTrials.gov registry record · Phase 2
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 2
A Phase 2 study of HIV and Alcohol Use Disorder, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06006143 is a Phase 2 study of HIV and Alcohol Use Disorder that is actively recruiting participants, run by Yale University. The registered enrollment target is 30 participants, below the 440-participant average among 303 other HIV trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06006143, a Phase 2 study of HIV and Alcohol Use Disorder, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This study seeks to determine the feasibility, acceptability, and preliminary efficacy of an intervention consisting of off-label use of a medication with strong efficacy data for alcohol use disorder (AUD) with medical management and a clinical pharmacist-delivered behavioral intervention in reducing alcohol use among individuals with HIV and AUD.
Conditions Studied
Interventions
- DRUG Varenicline
Study Locations (1)
Georgia
- Atlanta VA Medical Center - Decatur
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-06-16 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06006143
The ClinicalTrials.gov registry entry for NCT06006143 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 440-participant average among 303 other HIV trials with a reported enrollment target (93% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with HIV appearing as the primary indexed condition, and to 1 intervention - of which Varenicline is the first listed.
NCT06006143 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT06006143 about?
NCT06006143 is a clinical study titled "Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 2". This study seeks to determine the feasibility, acceptability, and preliminary efficacy of an intervention consisting of off-label use of a medication with strong efficacy data for alcohol use disorder (AUD) with medical management and a clinical pharmacist-delivered behavioral intervention in reduci...
What is the current status of trial NCT06006143?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2025-06-16. Estimated completion is 2025-12-31.
What conditions does trial NCT06006143 study?
This clinical trial studies the following conditions: HIV, Alcohol Use Disorder, Tobacco Use Disorder.
What interventions are being tested in trial NCT06006143?
The interventions under investigation include: Varenicline (DRUG).
Who is sponsoring clinical trial NCT06006143?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06006143 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV
RECRUITING · Phase 2
-
Improving Physical Ability and Cellular Senescence Elimination in HIV
RECRUITING · Phase 2
-
Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV
RECRUITING · Phase 2
-
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide
RECRUITING · Phase 2
-
Neuroactive Steroid to Treat Depressed Mood: A Trial for People With HIV
RECRUITING · Phase 2
-
A Study of VRC07-523LS, PGT121.414.LS, and PGDM1400LS Broadly Neutralizing Monoclonal Antibodies Given Intravenously in Adult Participants Without HIV
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.